Thrivent Financial for Lutherans
VNDA icon

Thrivent Financial for Lutherans’s Vanda Pharmaceuticals VNDA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,009
Closed -$123K – 2596
2024
Q1 		$123K Hold
30,009
– – ﹤0.01% 2485
2023
Q4 		$126K Sell
30,009
-1,465
-5% -$5.91K ﹤0.01% 2458
2023
Q3 		$136K Sell
31,474
-54,953
-64% -$305K ﹤0.01% 2403
2023
Q2 		$570K Sell
86,427
-2,868
-3% -$18.4K ﹤0.01% 2132
2023
Q1 		$606K Sell
89,295
-1,772
-2% -$12.5K ﹤0.01% 2047
2022
Q4 		$673K Sell
91,067
-421
-0.5% -$4.1K ﹤0.01% 1965
2022
Q3 		$904K Buy
91,488
+35,989
+65% +$380K ﹤0.01% 1747
2022
Q2 		$605K Buy
55,499
+10,145
+22% +$105K ﹤0.01% 2007
2022
Q1 		$513K Buy
45,354
+15
+0% +$197 ﹤0.01% 2183
2021
Q4 		$711K Buy
45,339
+366
+0.8% +$6.38K ﹤0.01% 2044
2021
Q3 		$771K Sell
44,973
-449
-1% -$7.86K ﹤0.01% 1976
2021
Q2 		$977K Buy
45,422
+337
+0.7% +$6.03K ﹤0.01% 1859
2021
Q1 		$677K Sell
45,085
-185
-0.4% -$3K ﹤0.01% 2094
2020
Q4 		$595K Sell
45,270
-132
-0.3% -$1.59K ﹤0.01% 2055
2020
Q3 		$439K Hold
45,402
– – ﹤0.01% 2032
2020
Q2 		$519K Buy
45,402
+701
+2% +$7.94K ﹤0.01% 1892
2020
Q1 		$463K Buy
44,701
+2,231
+5% +$27.7K ﹤0.01% 1756
2019
Q4 		$697K Buy
42,470
+189
+0.4% +$2.86K ﹤0.01% 1700
2019
Q3 		$561K Buy
42,281
+981
+2% +$13.7K ﹤0.01% 1768
2019
Q2 		$582K Buy
41,300
+1,214
+3% +$19.3K ﹤0.01% 1735
2019
Q1 		$738K Buy
40,086
+3,012
+8% +$68.6K ﹤0.01% 1571
2018
Q4 		$969K Buy
37,074
+815
+2% +$19.2K ﹤0.01% 1173
2018
Q3 		$832K Buy
+36,259
New +$740K ﹤0.01% 1409
2016
Q1 		– Sell
-93,060
Closed -$866K – 2029
2015
Q4 		$866K Buy
+93,060
New +$929K ﹤0.01% 1115

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans's VNDA Position: Q2 2024 in Review

Thrivent Financial for Lutherans sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 30,009 shares — an estimated $123K sold.

Thrivent Financial for Lutherans first reported a position in VNDA in Q4 2015 and held it in 24 quarters. The position peaked at $977K in Q2 2021. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Thrivent Financial for Lutherans reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 30,009 Vanda Pharmaceuticals shares in Q2 2024, an estimated $123K.
  • Thrivent Financial for Lutherans first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 24 quarters.
  • Thrivent Financial for Lutherans's Vanda Pharmaceuticals position peaked at $977K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2024, filed 13 Aug 2024.